Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 2.8% in the fourth quarter, HoldingsChannel reports. The fund owned 41,527 shares of the company’s stock after purchasing an additional 1,117 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Deciphera Pharmaceuticals were worth $670,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in DCPH. SG Americas Securities LLC raised its stake in shares of Deciphera Pharmaceuticals by 7.9% during the 3rd quarter. SG Americas Securities LLC now owns 165,016 shares of the company’s stock worth $2,099,000 after buying an additional 12,042 shares during the period. Sunesis Advisors LLC acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,225,000. Inspire Investing LLC raised its stake in shares of Deciphera Pharmaceuticals by 10.4% during the 3rd quarter. Inspire Investing LLC now owns 27,532 shares of the company’s stock worth $350,000 after buying an additional 2,583 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Deciphera Pharmaceuticals by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after buying an additional 997 shares during the period. Finally, Panagora Asset Management Inc. acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth approximately $1,167,000. 70.96% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Stock Performance

Shares of DCPH opened at $14.18 on Friday. Deciphera Pharmaceuticals, Inc. has a one year low of $9.90 and a one year high of $17.73. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -6.19 and a beta of 0.39. The stock has a 50 day moving average price of $15.61 and a 200 day moving average price of $14.28.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. During the same period in the previous year, the business earned ($0.60) earnings per share. The firm’s revenue for the quarter was up 32.9% on a year-over-year basis. On average, analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DCPH shares. JPMorgan Chase & Co. upped their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. Stifel Nicolaus boosted their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.